Fat Loss
Peptides commonly researched in the context of body-fat reduction, appetite regulation, and metabolic remodeling.
Body-composition changes are highly individual. Most peptides in this category are either prescription-only or not approved for general use.
Semaglutide
Strong Human EvidenceA GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy).
Tirzepatide
Strong Human EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).
Retatrutide
Moderate Human EvidenceAn investigational triple GLP-1 / GIP / glucagon receptor agonist showing the largest weight-loss effects yet seen in mid-stage trials.
MOTS-c
ExperimentalA mitochondrial-encoded peptide studied for its role in metabolism, exercise capacity, and mitochondrial signaling.
Tesamorelin
Strong Human EvidenceA long-acting GHRH analog FDA-approved as Egrifta for HIV-associated visceral fat accumulation.
AOD-9604
Limited Human EvidenceA 16-amino-acid C-terminal fragment of human growth hormone studied for fat metabolism, with disappointing weight-loss outcomes in humans.
5-Amino-1MQ
Animal / LabA small-molecule NNMT inhibitor studied in obese mice for reducing fat mass and raising cellular NAD+ and SAM levels.
Tesamorelin + Ipamorelin
ExperimentalA research stack combining tesamorelin (an FDA-approved GHRH analog for HIV-associated visceral fat) with ipamorelin, aimed at fat loss and growth-hormone support. No human trials exist on the combination itself.
PeptidePedia is for educational and informational purposes only. We do not sell peptides, prescribe peptides, provide medical advice, or recommend treatment. Peptides may not be approved for human use except in specific legal prescription or clinical contexts. Always consult a licensed medical professional before making health decisions.